ALAMEDA, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE:OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data highlighting its proprietary liquid biopsy test, which has the potential to determine which nodules are benign to reduce the number of unnecessary biopsies and associated complications, during the CHEST Annual Meeting 2019. This year's CHEST meeting is being held October 19-23, 2019 at the Ernest N. Morial Convention Center in New Orleans, LA.
Details of the poster discussion are as follows:
| Poster #: | E1101 |
| Title: | The Immune Response for Nodule Evaluation (IRENE) Cohort Profile |
| Presenter: | Lyndal Hesterberg, Ph.D. |
| Date: | Wednesday, October 23, 2019 |
| Time: | 10:15 a.m. – 10:20 a.m. CDT |
About OncoCyte Corporation
OncoCyte is a molecular diagnostics company providing actionable answers at critical decision points across the lung cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The company is currently developing a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence, allowing them to be treated when their cancer is still responsive to adjuvant chemotherapy. DetermaVu, the company's liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify which patients' lung nodules are benign, enabling them to avoid potentially risky biopsy procedures.
OncoCyte Forward Looking Statements
Investor Contacts
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]
Media Contact
Andrew Mielach
LifeSci Public Relations, LLC
646-876-5868
[email protected]
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
